biostudies-literaturePinsker JENIDDK NIH HHS635-642https://www.ebi.ac.uk/biostudies/studies/S-EPMC9422791biostudies-literatureUnknown24(9)<b><i>Background:</i></b> Automated insulin delivery (AID) systems have proven effective in increasing time-in-range during both clinical trials and real-world use. Further improvements in outcomes for single-hormone (insulin only) AID may be limited by suboptimal insulin delivery settings. <b><i>Methods:</i></b> Adults (≥18 years of age) with type 1 diabetes were randomized to either sensor-augmented pump (SAP) (inclusive of predictive low-glucose suspend) or adaptive zone model predictive control AID for 13 weeks, then crossed over to the other arm. Each week, the AID insulin delivery settings were sequentially and automatically updated by an adaptation system running on the study phone. Primary outcome was sensor glucose time-in-range 70-180 mg/dL, with noninferiority in percent time beDiabetes technology & therapeuticsOutpatient Randomized Crossover Comparison of Zone Model Predictive Control Automated Insulin Delivery with Weekly Data Driven Adaptation Versus Sensor-Augmented Pump: Results from the International Diabetes Closed-Loop Trial 4.PMC9422791P30 DK020541P30 DK036836UC4 DK108483K23 DK121942McCrady-Spitzer SLevy CJPatibandla NH Belle SKudva YCEggerman TLaffel LMNolander LIsganaitis EFreiner EBrooks DRaghinaru DBorgman SEkhlaspour LDassau ELum JWWysham CM Willi SChurch MMDesJardins DBeck RBuckingham BADoyle FJSimha VLegault LLevister CAmbler-Osborn LGreen JPinsker JEMurphy CArreaza-Rubin GKollman COgyaadu SPassman SCampos TGreen NiDCL Trial Research GroupDesrochers HDeshpande SShi DHsu LKaur RJPlesser MO'Malley GCastle JfalseOutpatient Randomized Crossover Comparison of Zone Model Predictive Control Automated Insulin Delivery with Weekly Data Driven Adaptation Versus Sensor-Augmented Pump: Results from the International Diabetes Closed-Loop Trial 4.<b><i>Background:</i></b> Automated insulin delivery (AID) systems have proven effective in increasing time-in-range during both clinical trials and real-world use. Further improvements in outcomes for single-hormone (insulin only) AID may be limited by suboptimal insulin delivery settings. <b><i>Methods:</i></b> Adults (≥18 years of age) with type 1 diabetes were randomized to either sensor-augmented pump (SAP) (inclusive of predictive low-glucose suspend) or adaptive zone model predictive control AID for 13 weeks, then crossed over to the other arm. Each week, the AID insulin delivery settings were sequentially and automatically updated by an adaptation system running on the study phone. Primary outcome was sensor glucose time-in-range 70-180 mg/dL, with noninferiority in percent time be2022-01-01T00:00:00Z2022 Sep2026-05-28T01:22:48.646Z2025-04-07T10:19:51.268ZS-EPMC94227913554970810.1089/dia.2022.0084